Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 22 July 2008
Vol. 1, Issue 29, p. re8
[DOI: 10.1126/scisignal.129re8]


Host-Directed Drug Targeting of Factors Hijacked by Pathogens

Anita Schwegmann and Frank Brombacher*

Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IIDMM), Faculty of Health Sciences, University of Cape Town and The International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa.

Gloss: Infectious diseases are a global health problem and have reached epidemic levels in developing countries. The current strategy for managing infectious diseases is to target unique biological processes or enzymes within pathogens in order to kill them. A serious disadvantage of this pathogen-directed drug targeting strategy has been the development of drug resistance and the resurgence of once-contained infectious diseases. Pathogens, especially those that reside within cells, hijack and subvert various host factors for their own growth and survival. Blocking interactions between pathogens and host factors that are essential for pathogen invasion, growth, and survival is a promising strategy to combat infectious diseases. In this Review with 1 figure, 1 table, and 124 references, we discuss the emergence of a drug discovery strategy that focuses on targeting propathogen host factors. We briefly review recent discoveries in this area, the strategies involved in identifying host drug targets, and the therapeutic modes of action of host-targeted drugs.

*Corresponding author. E-mail: fbrombac{at}

Citation: A. Schwegmann, F. Brombacher, Host-Directed Drug Targeting of Factors Hijacked by Pathogens. Sci. Signal. 1, re8 (2008).

Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation.
S. P. Parihar, R. Guler, R. Khutlang, D. M. Lang, R. Hurdayal, M. M. Mhlanga, H. Suzuki, A. D. Marais, and F. Brombacher (2014)
The Journal of Infectious Disease 209, 754-763
   Abstract »    Full Text »    PDF »
Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis.
M. McGrath, N. C. Gey van Pittius, P. D. van Helden, R. M. Warren, and D. F. Warner (2014)
J. Antimicrob. Chemother. 69, 292-302
   Abstract »    Full Text »    PDF »
Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response.
D. Yan, S. A. Krumm, A. Sun, D. A. Steinhauer, M. Luo, M. L. Moore, and R. K. Plemper (2013)
J. Virol. 87, 11076-11087
   Abstract »    Full Text »    PDF »
Cyclophilin Inhibitors Block Arterivirus Replication by Interfering with Viral RNA Synthesis.
A. H. de Wilde, Y. Li, Y. van der Meer, G. Vuagniaux, R. Lysek, Y. Fang, E. J. Snijder, and M. J. van Hemert (2013)
J. Virol. 87, 1454-1464
   Abstract »    Full Text »    PDF »
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.
H. E. Cummings, J. Barbi, P. Reville, S. Oghumu, N. Zorko, A. Sarkar, T. L. Keiser, B. Lu, T. Ruckle, S. Varikuti, et al. (2012)
PNAS 109, 1251-1256
   Abstract »    Full Text »    PDF »
Eradication of Intracellular Salmonella enterica Serovar Typhimurium with a Small-Molecule, Host Cell-Directed Agent.
H.-C. Chiu, S. K. Kulp, S. Soni, D. Wang, J. S. Gunn, L. S. Schlesinger, and C.-S. Chen (2009)
Antimicrob. Agents Chemother. 53, 5236-5244
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 15 July 2008.
J. F. Foley and A. M. VanHook (2008)
Science Signaling 1, pc6
   Abstract »    Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882